Gerben Lassche

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma

Maike J.M. Uijen, Gerben Lassche, Adriana C. H. van Engen–van Grunsven et al. · Oral Oncology · 2022 · 24 citations · Full text

Development and characterization of patient-derived salivary gland cancer organoid cultures

Gerben Lassche, Wim van Boxtel, Tilly Aalders et al. · Oral Oncology · 2022 · 23 citations · Full text

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade

Gerben Lassche, Yuichiro Tada, Carla M.L. van Herpen et al. · Cancers · 2021 · 18 citations · Full text

Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients

Gerben Lassche, Sjoerd van Helvert, Astrid Eijkelenboom et al. · Cancers · 2022 · 17 citations · Full text

DNA Methylation Profiling of Salivary Gland Tumors Supports and Expands Conventional Classification

Philipp Jurmeister, Maximilian Leitheiser, Alexander Arnold et al. · Modern Pathology · 2024 · 13 citations · Full text